Regeneron unveils new clinical data on metabolic, eye, and rare diseases at ADA and ENDO 2026.
Regeneron Pharmaceuticals announced it will present new clinical data and research on treatments for metabolic diseases, eye conditions, and rare diseases at the ADA and ENDO medical meetings in June 2026. Highlights include Phase 2 trial results on ...
